Clinical Trial

Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The investigators hypothesize that zanzalintinib in combination with ipilimumab and nivolumab will be well tolerated and serve as a potential therapeutic strategy in metastatic soft tissue sarcoma (mSTS) including myxofibrosarcoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, cutaneous angiosarcoma, and undifferentiated sarcoma histologies.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-08-12 -> 2029-02-12 2026-07-01
minor Completion pushed: 2031-07-31 -> 2034-01-31 2026-07-01
Trial Details
NCT Number NCT06968988
Lead Sponsor Washington University School of Medicine
Collaborators: Exelixis
Conditions Metastatic Soft-tissue Sarcoma
Enrollment 18 participants
Start Date 2026-01-05
Primary Completion 2029-02-12 (estimated)
Study Completion 2034-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-30